tachykinin precursor 4Genealiases: EK · HK-1 · PPT-C
Q-omics provides the consensus-scored TAC4 profile across patient tissues and cancer cell-line models. TAC4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TAC4 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TAC4 RNA expression shows 18,162 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, THCA, and THYM as cancer lineages where TAC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAC4 survival associations across molecular data types. TAC4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAC4 RNA expression–survival associations across cancer types. High TAC4 expression shows unfavorable associations in SCLC, ACC and KIRC, but favorable associations in LUAD, UCEC and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TAC4 RNA expression.
This table summarizes TAC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TAC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAC4 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, HNSC and LUAD. The THCA box plot shows higher TAC4 RNA expression in normal versus tumor tissue (log2 FC = −0.346, t-test p < 0.001).
This table shows molecular features associated with TAC4 in patient tissues and cancer cell lines. In patient samples, TAC4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
